FENC,Fennec Pharmaceuticals Inc. | Healthcare

Healthcare

FENC

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Fennec Pharmaceuticals Inc.FENC

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.

The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients.

It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Latest News >

Motorola Solutions Reports First-Quarter 2026 Financial Results

May 7, 2026

Company raises full-year revenue and earnings outlook driven by record Q1 orders and backlog Sales of $2.7 billion, up 7% versus a year ago Software and Services sales up 18% Products and Systems Integration sales up 1% GAAP earnings per share (EPS) of $2.18 Non-GAAP EPS* of $3.37 Record Q1 ending backlog of $15.7 billion, up 11% versus a...

Alarm.com Reports First Quarter 2026 Results

May 7, 2026

-- SaaS and license revenue increased 10.8% to $181.5 million, compared to $163.8 million for the first quarter of 2025 -- -- GAAP net income was $23.4 million, compared to $27.7 million -- -- Non-GAAP adjusted EBITDA was $49.6 million, compared to $45.8 million -- TYSONS, VA.--(BUSINESS WIRE)-- Alarm.com Holdings, Inc. ( ALRM ) , the leading platform for...

Grove Announces First Quarter 2026 Financial Results

May 7, 2026

SAN FRANCISCO--(BUSINESS WIRE)-- Grove Collaborative Holdings, Inc. ( GROV ) (“Grove” or the “Company”), the world’s first plastic neutral retailer and a leading sustainable consumer products company, certified B Corporation, and Public Benefit Corporation, today reported financial results for its fiscal first quarter ended March 31, 2026. Key First Quarter 2026 Financial Highlights: Total Net Revenue was $36.2 million, down...

Varex Announces Financial Results for Second Quarter Fiscal Year 2026

May 7, 2026

SALT LAKE CITY--(BUSINESS WIRE)-- Varex Imaging Corporation ( VREX ) today announced its unaudited financial results for the second quarter fiscal year 2026. Q2FY26 Summary Revenues $216 million GAAP gross margin 34% | Non-GAAP gross margin* 34% GAAP operating margin 7% | Non-GAAP operating margin* 9% GAAP net loss $0.19 per diluted share | Non-GAAP net income* $0.21 per diluted...